Generic Name and Formulations:
Metronidazole 0.75%; vaginal gel; contains parabens.
Medicis Pharmaceuticals Corp
- HPV Status Linked to Overall and Disease-free Survival in Vulvar Cancer
- FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Promising Activity Reported for Nivolumab in Gynecologic Cancers
- Vaginal Infection Treatments
- Risk Factors for Overactive Bladder and Urinary Incontinence
- Hormone Replacement Therapies
Indications for METROGEL-VAGINAL:
One applicatorful once daily at bedtime, or twice daily, for 5 days.
Discontinue if abnormal neurological signs develop. CNS or hepatic disease. Abstain from vaginal intercourse during therapy. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid concomitant alcohol. May potentiate oral anticoagulants, lithium. May be potentiated by cimetidine.
Superinfection, local irritation, GI discomfort/upset, headache, abnormal taste, dizziness, decreased appetite, change in WBC counts.
Gel—70g (w. applicators)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy